- Home
- RNAC
as 07-26-2024 4:00pm EST
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 437.2M | IPO Year: | 2016 |
| Target Price: | $42.60 | AVG Volume (30 days): | 276.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -56.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.67 - $42.60 | Next Earning Date: | 08-15-2024 |
| Revenue: | $25,906,000 | Revenue Growth: | -68.68% |
| Revenue Growth (this year): | -36.45% | Revenue Growth (next year): | -8.96% |
Stock Insider Trading Activity of Cartesian Therapeutics Inc. (RNAC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Mar 18 '24 | Buy | $0.60 | 19,044 | $11,397.83 | 31,073,406 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Mar 14 '24 | Buy | $0.54 | 648,372 | $351,676.97 | 30,516,862 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Mar 14 '24 | Buy | $0.59 | 537,500 | $314,545.00 | 31,054,362 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 17 '24 | Buy | $0.69 | 800 | $552.00 | 87,218 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 17 '24 | Buy | $0.65 | 800 | $520.00 | 88,018 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 17 '24 | Buy | $0.66 | 2,400 | $1,575.12 | 90,418 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 17 '24 | Buy | $0.66 | 4,800 | $3,186.72 | 95,218 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 17 '24 | Buy | $0.65 | 1,200 | $784.92 | 96,418 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 17 '24 | Buy | $0.61 | 1,200 | $734.64 | 97,618 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 17 '24 | Buy | $0.58 | 3,200 | $1,867.84 | 100,818 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 17 '24 | Buy | $0.53 | 2,000 | $1,061.00 | 102,818 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 17 '24 | Buy | $0.56 | 1,200 | $672.00 | 104,018 | SEC Form 4 |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 17 '24 | Buy | $0.61 | 800 | $488.00 | 104,818 | SEC Form 4 |
Latest Cartesian Therapeutics Inc. News
RNAC Breaking Stock News: Dive into RNAC Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
24 days ago
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Investor's Business Daily
24 days ago
Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs
GlobeNewswire
25 days ago
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
GlobeNewswire
25 days ago
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
GlobeNewswire
25 days ago
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
2 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
Compare RNAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAC Cartesian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.